CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Prestige Consumer Healthcare Inc. (PBH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Prestige Consumer Healthcare Inc. (PBH)

Pharmaceutical Preparations · market cap $2.2B · as of 2026-07-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Prestige Consumer Healthcare Inc. (PBH) is a Tarrytown, NY-based OTC healthcare and household cleaning products company with $2.2B market cap and ~$1.1B in annual revenue. Despite its consumer-staples profile, the company carries an unexpected clinical-stage pipeline including two Phase 3 assets (HD204 in Lung Cancer, HD201 in HER2+ Breast Cancer) and a Phase 2 asset (PBP1510 in Pancreatic Cancer), creating a structural anomaly between its branded OTC core business and biopharma-style pipeline catalysts. The next scheduled catalyst is an August 6, 2026 earnings report.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
HD204Phase 3Lung Cancer
PBP1510Phase 2Pancreatic Cancer
HD201Phase 3HER2 Positive Breast Cancer
Price & technical context
3-month
-7.7%
6-month
-1.2%
12-month
-23.7%
52-wk range
$42.98–$70.21
vs 50-day MA
-2.6%
vs 200-day MA
-13.1%
Realized vol
38.9%
Max drawdown
-51.8%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for PBH (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.